Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche by Govaere O et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Govaere O, Wouters J, Petz M, Vandewynckel Y-P, Van Den 
Eynde K, Van Den Broeck A, Verhulst S, Dolle L, Gremeaux L, 
Ceulemans A, Nevens F, Van Grunsven LA, Topal B, Vankelecom 
H, Giannelli G, Van Vlierberghe H, Mikulits W, Komuta M, 
Roskams T. 
Laminin-332 sustains chemoresistance and quiescence as part 
of the human hepatic cancer stem cell niche. 
Journal of Hepatology2016, 64(3), 609-617 
 
 
Copyright: 
2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license 
 
DOI link to article: 
https://doi.org/10.1016/j.jhep.2015.11.011 
 
Date deposited:   
08/12/2017 
  
Research ArticleLaminin-332 sustains chemoresistance and quiescence as part of
the human hepatic cancer stem cell niche
Olivier Govaere1,⇑, Jasper Wouters1, Michaela Petz2, Yves-Paul Vandewynckel3,
Kathleen Van den Eynde1, Anke Van den broeck4, Stefaan Verhulst5, Laurent Dollé5,
Lies Gremeaux6, An Ceulemans1, Frederik Nevens7, Leo A. van Grunsven5, Baki Topal4,
Hugo Vankelecom6, Gianluigi Giannelli8, Hans Van Vlierberghe3, Wolfgang Mikulits2,
Mina Komuta1, Tania Roskams1
1Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium; 2Department of Medicine I, Institute of
Cancer Research, Medical University of Vienna, Vienna, Austria; 3Department of Hepatology & Gastroenterology, Ghent University, Ghent,
Belgium; 4Department of Abdominal Surgery, KU Leuven and University Hospitals Leuven, Leuven, Belgium; 5Department of Biomedical Sciences,
Liver Cell Biology Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; 6Department of Development and Regeneration, KU Leuven, Leuven,
Belgium; 7Department of Hepatology, KU Leuven and University Hospitals Leuven, Leuven, Belgium; 8Department of Medical Biosciences and
Human Oncology, Padiglione Semeiotica Medica, Bari, ItalyBackground & Aims: Cancer stem cells (CSCs) are thought to be The effect of laminin-332 was enhanced upon mTORC1 inhibition
persistent in tumours due to their chemoresistance and to cause and diminished when inhibiting mTORC1+C2. Resistance to dox-
relapse and metastasis. Hepatic carcinomas displaying hepatic
progenitor cell (HPC) features have been associated with a poor
prognosis, though it remains unclear how CSCs relate to these dif-
ferent histological subtypes.
Methods: Candidate CSCs were isolated using the side population
(SP) technique from primary tissue samples diagnosed as keratin
(K)19-negative or -positive hepatocellular carcinoma (HCC) or as
combined hepatocellular/cholangiocarcinoma and analysed for
gene and protein expression. The effect of laminin-332 was anal-
ysed in vitro by using HCC cell lines and in vivo using a xenograft
mouse model.
Results: The size of the SP correlated with the degree of HPC fea-
tures found in human hepatic cancer, and also showed an ele-
vated mRNA expression of biliary/HPC markers and the
extracellular matrix marker LAMC2, the gene encoding the lami-
nin c2-chain. Immunopositivity for the c2-chain of laminin-332
was seen in the extracellular matrix surrounding small HPC-like
tumour cells with a low proliferation rate. In vitro, laminin-332
increased K19 expression, phosphorylated mTOR and decreased
phospho-histone H3 expression, indicating reduced cell mitosis.Journal of Hepatology 20
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Rapamycin; qPCR, quantitative real-time PCR; SP, side population.orubicin and sorafenib treatment, and the SP fraction increased in
the coated condition. In vivo, laminin-332 reduced tumour
growth and sustained K19 expression.
Conclusions: In this study we identified a prominent role for
laminin-332 as part of the specialised CSC niche in maintaining
and supporting cell ‘stemness’, which leads to chemoresistance
and quiescence.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Resistance to chemo- and radio-therapeutic treatment is a com-
mon phenomenon, especially in liver cancer. One possible expla-
nation for this phenomenon is the cancer stem cell (CSC) concept.
CSCs are cancer cells that possess characteristics associated with
normal stem cells, in particular their ability to give rise to all
tumour-derived cell types found in a cancer sample. Such cells
are proposed to be persistent in tumours due to their resistance
to classical chemotherapeutics and to cause relapse and metasta-
sis. However, although the concept of CSCs is intriguing and a
large number of experimental studies support the CSC hypothe-
sis, there are still open questions and room for caution [1]. One
debate concerns the origin of CSCs. Does the CSC derive initially
from a normal stem cell or from a dedifferentiated cell during
tumour progression?
The vast majority of primary liver cancers arise from liver
epithelial cells and is classically subdivided into hepatocellular
carcinomas (HCCs), cholangiocellular carcinomas (CCs) or com-
bined HCC/CC. An unresolved question regarding liver cancers
is which epithelial cells–hepatocytes, cholangiocytes, hepatic
progenitor cells (HPCs) or all three– have to be considered as16 vol. 64 j 609–617
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the cells of origin. Mature hepatocytes and cholangiocytes have
an enormous self-renewal capacity and longevity and so meet
the requisite to be targets for oncogenesis [2]. HPCs are a target
for carcinogenesis as well, since most of the hepatic cancers arise
in a background of chronic liver disease where there is an exten-
sive activation of the HPCs (seen as ductular reaction) [3]. In the
regenerating liver, HPCs reside in a specialised microenvironment
(the so-called niche), where interactions with the extracellular
matrix help decide their cell fate: a choice between differentia-
tion, proliferation or maintaining ‘stemness’. Laminins (Ln) are
a large family of extracellular matrix proteins mainly distributed
along the basement membrane and are comprised of three differ-
ent chains (a, b and c). They have been described to be part of the
specialised HPC niche in both human and mouse, where they are
thought to play a crucial role in sustaining HPC features [4,5]. In
the last decade, many laboratories have underlined the role of the
isoform-5, more recently renamed as Ln-332, in promoting
tumour progression and dissemination [6]. Our group previously
showed that the c2-chain of Ln-332 in particular was highly ele-
vated in HCCs expressing the biliary/HPC marker keratin (K)19
[7]. Other reports described the c2-chain as a poor prognostic
factor for patients diagnosed with a HCC or an intrahepatic CC
[8,9]. Ln-332 can interact with the integrin a3b1 and/or the inte-
grin a6b4 receptor and has been reported to increase resistance
to gefitinib, an inhibitor of epidermal growth factor receptor, in
HCC cell lines in vitro [10]. Whether Ln-332 is part of the CSC
niche in hepatic cancer and whether it can influence the beha-
viour of CSCs remains unclear. In small cell lung cancer Ln-
integrin interactions attenuate cell survival and chemoresistance
through activation of the mammalian target of rapamycin
(mTOR) axis [11]. mTOR has been described as a central regulator
of cell growth, metabolism and survival [12]. We therefore
hypothesised that mTOR could be potentially involved in regulat-
ing the hepatic CSC phenotype.
In this study, we aim to characterise the CSC niche in different
histopathological subtypes of hepatic carcinomas, reflecting their
possible cell of origin. To isolate putative CSCs, the side popula-
tion (SP) technique was used (based on the functional ability of
the ATP-binding cassette transporters to efflux the fluorescent
dye Hoeschst33342), which has proven to be useful in HCC cell
lines to isolate cells with a ‘stemness’ signature that show an
increased ability for tumour-initiation and chemoresistance
[13–16]. Identification and characterisation of the SP was per-
formed using qPCR and immunohistochemistry. In addition, the
influence of Ln-332 on ‘stemness’ traits, such as chemoresistance
and quiescence, and potential downstream targets, such as HPC
markers, was investigated in vitro and in vivo.Material and methods
Human tissue samples
Eighteen patients diagnosed with an hepatic carcinoma between 2008 and 2012
at the University Hospitals in Leuven (Belgium) were included in this study.
Immediately after surgical removal of the tumour (resection samples), part of
the tissue was fixed in 6% formalin and embedded in paraffin, while the other part
was stored in RecoveryTM Cell Culture Freezing Medium (Invitrogen, Carlsbad, CA,
USA) in liquid nitrogen. The histopathological diagnosis of HCCs or combined
HCC/CCs was performed according to the World Health Organization criteria.
Fibrolamellar HCCs were not included. HCCs were further subdivided into K19-
negative and K19-positive HCCs as previously described [17]. The study was
approved by the ethical committee of the University Hospitals Leuven, Belgium.610 Journal of Hepatology 201Side population analysis
SP analysis was performed as previously published [7]. A detailed description can
be found in the Supplementary material. In short, frozen samples were thawed
and dissociated using LiberaseBlendzyme 3 (0.8 Wunsch unit/ml, 1.5 h, 37 C)
(Roche, Basel, Switzerland). Single cell suspension was incubated with 5 lg/ml
Hoechst33342 (Sigma-Aldrich, St Louis MO, USA) for 90 min at 37 C. The ABC-
transporter inhibitor Verapamil (100 lM; Sigma-Aldrich) was used to assess
the SP phenotype from the rest of the main population (MP); propidium iodide
(2 lg/ml; Sigma-Aldrich) to exclude dead cells. Samples were analysed using a
FACSAriaII (BD Biosciences) under UV excitation (450/50, 675/20 filter).
The size of the SP was calculated as percentage of the total viable population.
Median cell size of SP and MP was analysed based on the Forward Scatter Area
(FSC-A). Sorted cells were fixed using BD CytoRichTM System (BD Biosciences)
and processed into cytospins for Papanicolaou stainings or immunocytochemistry.
Part of the sorted cells out of twelve patient samples (four per histological group)
was processed for qPCR analysis. The description of the qPCR method and the list
of primers can be found in Supplementary material and Supplementary Table 1.
Immunohistochemistry/immunocytochemistry
Five-micrometre-thick human formalin-fixed paraffin-embedded (FFPE) tissue
slides and cytospins were stained with the Leica BOND-MAXTM system (Leica
Microsystems GmbH, Wetzlar, Germany), using the Novocastra Bond Polymer
Detection Kit (Leica). Visualisation was done using DAB-Chromogen, followed
by a haematoxylin counterstaining. Cultured primary cells and cell lines were
stained using BrightVision Poly-HRP (Immunologic, Duiven, The Netherlands)
and visualised with 3-amino-9-ethylcarbazole. Primary antibodies were directed
against ABCB1/MDR1 (1/10 for FFPE slides, 1/100 for cytospins; Monosan, Uden,
The Netherlands), ABCG2/BCRP (1/5 for FFPE slides, 1/100 for cytospins; Santa
Cruz Biotechnology, Dallas, Texas, USA), K19 (1/25; Dako, Glostrup, Denmark),
c2-chain of Ln-332 (1/500; Sigma-Aldrich), Ln-332 (an antibody recognizing
the complete protein, 1/100; Abcam, Cambridge, UK), phospho-mTOR (pmTOR,
Ser2481; 1/50; Cell Signaling, Danvers, MA, USA) and phospho-Histone H3
(pHH3; 1/100; Millipore, Billerica, MA, USA).
Immunofluorescence
Human FFPE samples were deparaffinised, processed for epitope retrieval and
stained for c2-chain of Ln-332+K19 or c2-chain of Ln-332+Ki67 (ready-to-use,
Dako) for 45 min. Cell culture samples were fixed in 4% formaldehyde solution
and stained for K19+pHH3 for 45 min. Afterwards samples were incubated for
30 min with Alexa Fluor 568 Goat Anti-Rabbit and Alexa Fluor 488 Goat
Anti-Mouse (1/100, Invitrogen). Samples were counterstained with DAPI (Invitro-
gen). Fluorescent signals were observed using Zeiss Axioplan (Carl Zeiss, Oberko-
chen, Germany).
In vitro growth potential of primary samples
To assess the in vitro growth potential of primary human hepatic cancer, dissoci-
ated primary tissue samples (n = 2 per histological group) were grown in Advanced
Dulbecco’s Modified Eagle’s Medium (Invitrogen), supplemented with 10% heat-
inactivated Fetal Bovine Serum and L-Glutamine (Invitrogen); at 37 C in a humid-
ified chamber supplementedwith 5% CO2. Cells that showed growth potential were
passed on and characterised by immunocytochemistry at twelve weeks.
In vitro Ln-332 coating experiments
Characterisation cell lines
Human HCC cell lines PLC/PRF/5, HepG2 (ECACC, Salisbury, UK) and Hep3B2
(ATCC-LGC Standards, Molsheim Cedex, France) were grown in similar conditions
as the dissociated human samples. Cells were processed into FFPE tissue blocks
using the Cellient Automated Cell Block System (Hologic, Bedford, MA, USA) and
stained for K19, c2-chain of Ln-332 and integrin a6 receptor chain (ITGA6;
1/50; Sigma-Aldrich) expression using immunohistochemistry as described above.
mRNA expression
Six-well cell culture plates were coated with Ln-332 (Biolamina, Stockholm, Swe-
den) at a concentration of 2 lg/cm2 (1.5 h, 37 C) and seeded with 6  105 HCC
cells (n = 3 per cell line). After 72 h the cells were harvested for mRNA extraction
and processed for qPCR analysis (Supplementary material).6 vol. 64 j 609–617
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Protein expression
The effect of Ln-332 on protein expression was accessed using HepG2 cells
(n = 4), grown in 8-well cell culture slides, by means of immunocytochemistry
(see above). Immunopositive cells were counted in five representative high power
fields. Additionally HepG2 cells were treated with mTOR inhibitors rapamycin
(10 nM) or WYE-687 (5 lM) (Selleckchem, Tx, USA) and analysed by immunoflu-
orescence. Determination of the IC50 value for WYE-687 in HepG2 cells can be
found in Supplementary material and Supplementary Fig.1.
Chemosensitivity
HepG2 cells, grown in coated and non-coated conditions for 72 h, were treated
with Doxorubin (1 lM and 20 lM) or Sorafenib (1 lM, 10 lM and 20 lM)
(Selleckchem) for 48 h. Proliferative activity was assessed by bromodeoxyuridine
(BrdU) labelling (Roche, Mannheim, Germany), according to manufacturer’s
instructions. Experiments were performed in quadruplicate.
Stemness features
Coated and non-coated HepG2 cells were submitted to SP analysis (n = 3) using
5 lg/ml Hoechst33342 with or without Verapamil at 50 lM (Sigma-Aldrich). Col-
ony forming assays were performed by seeding 500 HepG2 cells in coated and
non-coated 6-well plates (n = 3). After ten days, cells were visualised with a
Giemsa stain (Sigma-Aldrich) and counted using a brightfield microscope.
Xenograft models
Six- to eight-week-old NOD.CB17-Prkdcscid/NCrHsd mice (Harlan, Boxmeer, The
Netherlands) were injected subcutaneously with 3  106 HepG2 cells in a total
volume of 200 ll, consisting of Dulbecco’s Modified Eagle’s Medium with or with-
out supplement: either Ln-332 (40 ll of the total volume; Biolamina) or Matrigel
(100 ll of the total volume; Corning, NY, USA) or both. This categorised the ani-
mals into four groups (2 animals per group, injected at both flanks): HepG2,
HepG2+Ln-332, HepG2+matrigel and HepG2+matrigel+Ln-332. Uponmacroscopic
observation of the first tumour nodule, tumour dimensions were measured daily
using the following formula: volume (mm3) = ab2/2, where b was the smaller
dimension. All animals were sacrificed at day 10, calculated from the time point
when the first tumour nodule was observed. Samples were processed into FFPE
blocks and processed for K19-immunostaining and haematoxylin-eosin staining.
Statistical analysis
Statistical qPCR analysis was performed using the Mann-Whitney U test, the
unpaired/paired Student’s t test and the two-way mixed ANOVA with GraphPad
Prism 5.02 (GraphPad Software, Inc., La Jolla, CA, USA). All analyses were two-
tailed. In all cases, p <0.05 was considered significant.Results
Side population proportion correlates with the degree of hepatic
progenitor cell features
Candidate CSCs were isolated using the SP method, a technique
based on the functional ability of the ATP-binding cassette trans-
porters to efflux the fluorescent dye Hoeschst33342. Using the
ABCB1/MDR1 blocker verapamil, an SP was identified ranging
from 0.60 to 32.50%. The hepatic carcinomas were subdivided
into three groups corresponding to their presumed cell of origin.
Flow cytometric analysis showed that the average SP proportion
varied from 3.43% (±2.27) in K19-negative HCCs (n = 7) to 9.29%
(±4.42) in K19-positive HCCs (n = 7) and 15.43% (±13.98) in the
combined HCC/CC (n = 4); showing that the size of the CSC
population inclines with the degree of HPC features (Fig. 1). The
SP proportion of K19-negative HCCs was significantly smaller
than that of the K19-positive HCCs (p <0.01) and the combined
HCC/CC (p <0.05).
To assess the overlap with ABCG2, a transporter which can
also be targeted to obtain the SP phenotype, cytospins of sortedJournal of Hepatology 201human cells were stained for MDR1 and ABCG2 [18]. The SP
showed an increased expression of both MDR1 and ABCG2 com-
pared to the MP (Fig. 1). In human FFPE samples, MDR1 as well as
ABCG2 showed a gradient of immunoreactivity throughout all the
tumour samples, with the strongest in small to intermediate-
sized tumour cells (Supplementary Fig. 2). In the non-neoplastic
surrounding tissue, MDR1 and ABCG2 were highly expressed in
the HPCs.
Analysis of the median cell size of each sample showed that SP
contained smaller cells compared to the MP (significantly differ-
ent in the K19-positive HCC and combined HCC/CC group)
(Fig. 1). Morphologically the SP fraction contained small sized
cells with a high nucleus-cytoplasm ratio, while the MP con-
tained larger tumour cells with a low nucleus-cytoplasm ratio
(Fig. 1).
Side population displays elevated expression of hepatic progenitor
cell markers
Sorted samples were analysed by qPCR to examine the purity and
to investigate biliary/HPC/stemness features. Compared to the
MP, the SP of each group showed significantly elevated expres-
sion for the biliary/HPC markers KRT19, KRT7 and TACSTD2, the
extracellular matrix marker LAMC2 and the ABC-transporter
MDR1 (Table 1). In addition, the SP of the K19-negative HCCs
showed a significantly higher expression compared to their
respective MP for CD133, TWEAKR, JAG1, LAMB1, ITGA3, ITGB4,
MUC1 and ALB; the SP of the K19-positive HCCs for EPCAM,
TWEAKR, CXCR4, ITGA6 and ITGB1; and the SP of the combined
HCC/CC for EPCAM and ITGA3. ITGA3 was significantly reduced
in the SP of K19-positive HCCs. No significant differences were
found for the biliary/HPC marker SOX9 or the ABC-transporters
MRP1, MRP2, MRP3 and ABCF2. The mesenchymal markers VIM
and aSMA, the hematopoietic marker CD45 and the endothelial
marker CD31 were not significantly differentially expressed, sug-
gesting that these cell types are not overrepresented in either SP
or MP. A comparison of the different SP fractions for each group
can be found in Supplementary Fig. 3.
c2-chain of Ln-332 immunopositivity correlates with K19 expression
and a low proliferation ratio
Since mRNA expression levels of the biliary/HPC marker KRT19
and the extracellular matrix marker LAMC2 (encoding the c2-
chain of Ln-332) were upregulated in the SP of each histological
group, we aimed to analyse their protein expression in vivo using
immunohistochemistry. As expected, K19-negative HCCs showed
no positivity for K19 on protein levels (Fig. 2), while immunore-
activity for the c2-chain of Ln-332 was only observed focally in
the cytoplasm and in the surrounding of small tumour cells. In
K19-positive HCCs, K19 displayed a submembranous staining
pattern, prominently in small to intermediate-sized cells (Fig. 2).
The c2-chain staining pattern was similar to K19-negative HCCs,
though the number of positive cells was noticeably higher in the
K19-positive HCCs. Combined HCC/CCs showed a strong
immunopositivity for K19 in the cholangiocytic differentiated
area and the ductular area, and a scattered positivity in the
hepatocytic differentiated area (Fig. 2). The c2-chain of Ln-332
was prominently expressed in the ductular area. In the surround-
ing non-tumoural tissue, the c2-chain was seen as part of the
extracellular matrix surrounding the K19-positive HPCs. Focally,6 vol. 64 j 609–617 611
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Fig. 1. Side population (SP) in human hepatic carcinomas. SP phenotype is based on the functional ability of stem-like cells to efflux the fluorescent dye Hoechst3342.
The ABC-transporter blocker verapamil was used as a control. (A) Flow cytometric analysis showed that the mean SP proportion in the hepatic carcinomas gradually
increased with the degree of HPC features (unpaired Student’s t test; ⁄⁄p <0.01; ⁄p <0.05). (B) Median cell size was calculated for each sample based on the Forward Scatter
Area (FSC-A). Results are displayed as average fold FSC-A of the SP compared to the main population (MP) for each histological group (paired Student’s t test; ⁄p <0.05). Flow
cytometry plots show the SP, MP and all events of a representative K19-positive HCC. (C) Immunocytochemistry for MDR1 and ABCG2 was performed on the sorted SP and
MP of each human sample (n = 18). Panel (C) shows the MRD1 and ABCG2 expression in a representative sorted K19-negative HCC sample. (D–F) Representative example of
a SP plot of the different histological subtypes. Morphologically the SP fraction contained small to intermediate-sized cells with scan cytoplasm, while the MP contained
larger tumour cells (Scale bars 50 lm).
Research Articlea single HPC was observed to show cytoplasmic positivity for the
c2-chain of Ln-332 (Fig. 2, arrow). Additionally, c2-chain
immunopositivity was noted in parts of the inflammatory cells
and endothelial cells in both tumour tissue as surrounding liver
tissue.
Immunofluorescent double stainings showed that K19 and the
c2-chain of Ln-332 were strongly co-expressed in the ductular
area of the combined HCC/CCs, whereas the c2-chain was low
in the hepatocytic differentiated area where a gradual loss of
K19 was noted (Fig. 3A). Moreover, in areas where the c2-chain
of Ln-332 was strongly present, the Ki67 nuclear positivity was
reduced, indicating a lower proliferation rate (Fig. 3A).
Only the dissociated primary combined HCC/CCs showed
capacity to survive in standard cell culture conditions. Character-
isation by immunocytochemistry (at passage 12) revealed that612 Journal of Hepatology 201these cells were positive for K19, the c2-chain of Ln-332 and
the complete protein Ln-332 (Fig. 3B).
Ln-332 induces K19 expression, quiescence and chemoresistance
in vitro
In view of the strong correlation between the c2-chain of Ln-332
and HPC morphology (K19 expression and low proliferation
index), we focused on the influence of Ln-332 in vitro to assess
whether it has a direct effect on ‘stemness’ features of hepatic
carcinomas. The Hep3B2 cell line was found to be positive for
K19, c2-chain of Ln-332 and integrin a6 (ITGA6) (Fig. 4A). HepG2
showed focal positivity for K19, low to no expression for the
c2-chain and strong positivity for ITGA6. PLC/PRF/5 was negative
for all three markers. After a period of 72 h, Ln-332 coating6 vol. 64 j 609–617
Table 1. Side population displays elevated expression of hepatic progenitor cell markers.
Gene Description Fold expression SP/MP
K19 neg HCCs K19 pos HCCs Combined HCC/CC
Progenitor cell markers
KRT19 Keratin 19 2.90 (p <0.05) 4.82 (p <0.05) 6.28 (p <0.01)
KRT7 Keratin 7 7.14 (p <0.05) 8.99 (p <0.05) 5.47 (p <0.05)
EPCAM Epithelial cell adhesion molecule 1.52 4.67 (p <0.05) 2.02 (p <0.01)
TACSTD2/TROP2 Tumor-associated calcium signal transducer 2 22.32 (p <0.01) 5.52 (p <0.05) 7.50 (p <0.05)
PROM1/CD133 Prominin 1 7.50 (p <0.05) 201.2 1.22
SOX9 SOX9 SRY (sex determining region Y)-box 9 3.24 0.82 1.36
TNFRSF12A/TWEAKR Tumor necrosis factor receptor superfamily, member 12A 5.60 (p <0.01) 2.31 (p <0.05) 2.3
CXCR4 Chemokine (C-X-C motif) receptor 4 0.71 3.19 (p <0.05) 0.84
JAG1 Jagged 1 (Alagille syndrome) 10.67 (p <0.05) 1.65 2.98
ATP-binding cassette transporters
ABCB1/MDR1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 1.81 (p <0.05) 10.11 (p <0.05) 6.45 (p <0.05)
ABCC1/MRP1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 1.36 6.24 0.47
ABCC2/MRP2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 42.29 20.3 0.27
ABCC3/MRP3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 19.61 35.68 2.41
ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 2.68 1.71 0.12
Laminin and integrin receptors
LAMB1 Laminin, beta 1 4.40 (p <0.05) 8.14 0.31
LAMC2 Laminin, gamma 2 18.54 (p <0.01) 6.12 (p <0.05) 15.63 (p <0.05)
ITGA3 Integrin, alpha 3 11.85 (p <0.01) 0.04 (p <0.05) 2.10 (p <0.05)
ITGA6 Integrin, alpha 6 1.53 10.49 (p <0.01) 1.7
ITGB1 Integrin, beta 1 1.23 3.87 (p <0.05) 0.58
ITGB4 Integrin, beta 4 2.95 (p <0.01) 2.26 1.04
Biliary marker
MUC1/EMA Mucin 1, cell surface associated 9.98 (p <0.05) 2.72 4.05
Hepatocytic marker
ALB Albumin 6.13 (p <0.05) 1.36 1.78
Mesenchymal markers
VIM Vimentin 0.75 1.21 1.23
Endothelial marker
PECAM1/CD31 Platelet/endothelial cell adhesion molecule 0.37 0.41 0.37
Hematopoietic marker 
PTPRC/CD45 Protein tyrosine phosphatase, receptor type, C 0.38 2.63 0.21
JOURNAL OF HEPATOLOGYsignificantly increased mRNA expression of KRT19, TACSTD2 and
KLF4 in HepG2, and KRT19, EPCAM, CD133/PROM1 and JAG1
expression in Hep3B2 cells. No differences were noticed in the
PLC/PRF/5 cell line (Fig. 4B).
Using HepG2 as a model focally positive for K19 and low/neg-
ative for the c2-chain of Ln-332, Ln-332 coating increased the
number of K19-positive tumour cells and the phosphorylation
of mTOR (Ser2481), and reduced the expression of the mitotic
marker pHH3 (Fig. 4C, D). Morphologically, coated cells grew less
in clusters and had irregular shapes with extended filopodia for-
mation. Treatment (72 h) of coated HepG2 cells with rapamycin
(mTORC1 inhibitor) ameliorated the effect of Ln-332, more K19
and less pHH3 expression, while treatment with WYE-687
(mTORC1+C2 inhibitor) diminished this effect (Fig. 4D, E).
After 72 h Ln-332 coated HepG2 cells displayed an increased
SP fraction of 3.00 ± 1.28% compared to 0.17 ± 0.15% found in
non-coated cells (Fig. 4F). Additionally Ln-332 coating signifi-
cantly increased resistance to doxorubicin (20 lM) or sorafenib
(10 lM and 20 lM) treatment (Fig. 4G).
HepG2 cell colony formation assays showed that Ln-332
improved survivability after a period of ten days. Intriguingly,Journal of Hepatology 201the growth pattern of the coated cells was observed as scattered
single cells rather than clonogenic colonies, suggesting induction
of cell quiescence (Fig. 5A).
Ln-332 delays tumour growth and sustains K19 expression in vivo
The in vivo effect of Ln-332 was investigated in a subcutaneous
xenograft model injected using HepG2 cells with or without
matrigel and/or Ln-332. Tumour formation was observed in both
flanks of each animal, with the exception of one animal (HepG2
+Ln-332 group), which only formed a tumour on one flank.
Four weeks after tumour inoculation, tumour growth was first
observed in an animal injected with HepG2+matrigel. From that
time point all animals were monitored daily for a total period
of ten days and then sacrificed. Ln-332 significantly reduced
tumour growth either with or without matrigel injection
(Fig. 5B, C). Mixed model ANOVA analysis of the growth curves
can be found in Supplementary Table 2. Morphologically,
tumours injected with Ln-332 displayed more stromal and
microvascular invasion, as well as invasion in the underlying
muscular layer, compared to the tumours that were not injected6 vol. 64 j 609–617 613
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Research Articlewith Ln-332 (Fig. 5C; Supplementary Fig.4). In addition, tumours
injected with Ln-332 showed a higher expression of K19, which
appears scattered throughout the tumour with a concentration
at the invasive front (Fig. 5D; Supplementary Fig.4).Discussion
Current therapeutic strategies for the treatment of hepatic can-
cer mostly focus on the inhibition of tumour growth, though the
results are often unsatisfactory [19]. A prerequisite for the
development of new therapies is a good understanding of
tumour behaviour and, in particular, understanding the resistant
CSC population. The occurrence of HPC markers in hepatic can-
cer (e.g. HCCs) has been used for prognostic stratification, how-
ever to date the relationship between CSCs and HPC features
remains unclear [20]. In this study we showed that the size of
the CSC fraction (isolated based on the functionality of their
ABC-transporters) gradually increases with the degree of HPC
features found in hepatic carcinomas, reflecting the possible cell
of origin. Holczbauer et al. recently found similar results in
mice, reporting that the SP/CSC population is the largest in cell
lines derived from HPCs, when comparing immortalized cell
lines from different hepatic lineage (e.g. hepatocytes, HPCs
and hepatoblasts) [21]. One important player that determines
the behaviour of stem cells in general is their specialised614 Journal of Hepatology 201microenvironment [22]. We especially focused our study on
the role of the c2-chain of Ln-332 as our group previously
showed that its expression was associated with HPC features
in HCCs and as other groups described it as a poor prognosis
indicator in hepatic cancer [7,23]. Importantly, this current
study showed that the c2-chain was part of the neoplastic
CSC niche, as well as the non-neoplastic HPC niche, more
specifically in tumour areas with a low proliferation rate and
high K19 expression. In vitro, Ln-332 induced a phenotype
switch in hepatic carcinoma cells by pushing them towards a
more quiescent cell state and a more biliary/HPC phenotype
[24,25]. The Ln-332-induced cell phenotype interestingly proved
to be more resistant to doxorubicin and sorafenib treatment.
Quiescence and chemoresistance are regarded as typical
characteristics of both CSCs as well as normal stem cells [26].
Previous studies in glioblastoma, colorectal and pancreatic can-
cer showed that slow-cycling tumour cells in a reversible state
of quiescence are actually responsible for chemoresistance and
recurrence [27–29]. Remarkably, Ln-332 not only protects hep-
atic cancer cells against chemotherapy but stimulates cell prolif-
eration upon sorafenib exposure. In xenograft mouse models6 vol. 64 j 609–617
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JOURNAL OF HEPATOLOGYderived from primary urothelial carcinomas, cytotoxic
chemotherapy induces proliferation of a sub-fraction of the
tumour cells, more preciously the K14-positive ones, despite
the reduction seen in the tumour size [30]. So it might be pos-
sible that Ln-332 induces quiescence in hepatic cancer under
‘normal’ circumstances and that once under cellular stress (e.g.
sorafenib treatment) these cells react by enhanced proliferating.
Laminin-mediated activation of the mTOR pathway has been
reported to induce cell survival and chemoresistance in small cellJournal of Hepatology 201lung cancer [11]. The mTOR kinase has multiple downstream
effects depending on which distinct protein complex it forms, ter-
med mTORC1 and mTORC2 [31]. The mTORC1 complex promotes
cell growth by inducing metabolic processes in response to nutri-
ents and oxygen, whereas the mTORC2 complex responds to
growth factors and regulates cell survival, as well as the
cytoskeleton [12]. Our study shows that the effect of Ln-332 is
mTORC2-dependent, which is further enhanced upon mTORC1
inhibition (more K19 expression and quiescence). Presumably,6 vol. 64 j 609–617 615
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616 Journal of Hepatology 201there is a shift towards mTORC2 activation, driving the cells into
‘survival mode’.
Rictor, a binding partner of the mTORC2 complex, has
recently been linked with early recurrence after curative
treatment and poor overall survival in patients diagnosed with
HCC [32]. Marquardt et al. reported that when treating HCC
cell lines with zebularine, a DNA methyltransferase-1 inhibitor,
the SP fractions showed a differential expression of Rictor,
associated with an increase in the expression of biliary/HPC
cell markers (e.g. KRT19) [16]. The possible link between
mTORC2 and Ln-332-induced phenotype switching could
have a huge impact on current on-going clinical trials. It might
explain why rapamycin, a specific mTORC1 inhibitor, fails its
benefit as adjuvant therapy, as it presumably misses its effect
on CSCs.
Even though we found a CSC fraction in each histological
group, Ln-332 failed to induce ‘stemness’ markers in the
PLC/PRF/5 cell line, characterised as K19-negative. The lack of
expression of the ITGA6, one of the receptor subunits for
Ln-332, in this cell line could explain why no differences were
observed. The presence or absence of specific markers/receptors
might reflect the cell of origin [33].
The SP of the K19-positive HCCs is unique in its high
expression of CXCR4, a typical CSC marker linked with lymph
node metastasis and poor survival in human HCCs [34]. CXCR4
expression was observed at the tumour border as well as in
small cells scattered in the tumour bulk, similar to the K19
expression pattern as seen in the human samples and in the
xenograft models (Supplementary material). This underlines
the complex nature of CSCs. Further research in localisation
of CSCs and how they interact with their environment will be
necessary.
The future challenge in treatment of hepatic cancer will not
only be to reduce tumour growth, but also to target CSCs and
their specialised niche. As the CSC phenotype differs depending
on the histological subtype, a more personalised treatment would
be required for each individual patient diagnosed with hepatic
cancer.
Our study demonstrates that tumour behaviour is plastic and
depends on the microenvironment of the tumour cell. We partic-
ularly identified an important role for Ln-332 and more specifi-
cally its c2-chain as part of the specialised CSC niche in
maintaining and supporting ‘stemness’, e.g. quiescence and
chemoresistance. Therefore, monoclonal antibody treatment tar-
geting the c2-chain of Ln-332 could provide an innovative ther-
apy of hepatic cancer.Fig. 5. Ln-332 promotes survival and delays tumour growth. (A) Colony
forming assay for HepG2 cells in coated and non-coated condition (t = 10 d, n = 3).
Cells were visualised and quantified for each well (unpaired Student’s t test;
⁄⁄p <0.01). (B) HepG2 cells were subcutaneously injected in NOD/SCID mice.
Animals were categorised into four groups: HepG2, HepG2+Ln-332, HepG2
+matrigel and HepG2+matrigel+Ln-332. After four weeks tumour growth was
observed. From that time point all animals were monitored daily for a total period
of ten days and then sacrificed. (Mixed model ANOVA; ⁄p <0.05; detailed
statistical analysis: see Supplementary material). (C) Macroscopic picture (left)
and haematoxylin-eosin staining (right) of xenograft tumours obtained from
HepG2+matrigel injected either with or without Ln-332. Arrow indicates
microvascular invasion. (D) Immunohistochemistry was used to examine the
effect of Ln-332 on K19 expression in the xenograft models (Scale bars 200 lm).
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